Clinical Trials Logo

Malaria, Falciparum clinical trials

View clinical trials related to Malaria, Falciparum.

Filter by:

NCT ID: NCT00988507 Terminated - Clinical trials for Plasmodium Falciparum Infection

Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

FARM
Start date: October 2009
Phase: Phase 2
Study type: Interventional

Primary objective: To assess the Day 28 efficacy defined as the percentage of patients with no parasitic recrudescence, of 3 treatment groups - 3 dose levels of ferroquine associated with artesunate - for a 3-day treatment. Secondary objectives: - To assess the efficacy of ferroquine at one dose level alone for a 3-day treatment. - To assess the clinical safety of 4 treatment groups - 3 dose levels of ferroquine associated with artesunate and one dose level of ferroquine alone. - To assess pharmacokinetics parameters of ferroquine and its metabolites along sparse sampling schedules.

NCT ID: NCT00400101 Terminated - Falciparum Malaria Clinical Trials

Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides

Start date: November 2003
Phase: Phase 1
Study type: Interventional

Influenza virosomes represent an innovative human-compatible antigen delivery system that has already proven its suitability for subunit vaccine design. The aim of the study was to proof the concept that virosomes can also be used to elicit high titers of antibodies against synthetic peptides derived from the circumsporozoite protein and from the apical-membrane-antigen 1 and that the formulations are safe in humans.

NCT ID: NCT00374205 Terminated - Malaria, Falciparum Clinical Trials

Randomized Trial on Effectiveness of ACTs in Ghana

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effectiveness and safety of two Artemisinin Combination Therapies (ACTs) for the treatment of children with uncomplicated Plasmodium falciparum malaria

NCT ID: NCT00304980 Terminated - Clinical trials for Plasmodium Falciparum Malaria

Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status

Start date: March 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of sulfadoxine-pyrimethamine (SP) versus artemether-lumefantrine (Coartem) when administered to HIV+ and HIV- patients with uncomplicated P. falciparum malaria. Patients will be randomised to one of the 2 treatment and followed up (until day 14 actively) for 45 days.

NCT ID: NCT00133393 Terminated - Clinical trials for Plasmodium Falciparum Malaria

Pentoxifylline in Children With Malaria

Start date: January 2002
Phase: Phase 2
Study type: Interventional

The primary objectives of this study is to identify a safe, tolerable dose of pentoxifylline in children with cerebral malaria and to establish an acceptable pentoxifylline dosage regimen for use in multi center Phase II and Phase III studies.

NCT ID: NCT00084240 Terminated - Malaria, Falciparum Clinical Trials

Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia

Start date: March 2004
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective is to confirm the hypothesis that azithromycin (optimal dose once daily for three days) plus chloroquine is non-inferior to sulfadoxine-pyrimethamine plus chloroquine for the treatment of uncomplicated, symptomatic malaria due to P. falciparum.

NCT ID: NCT00082563 Terminated - Malaria, Falciparum Clinical Trials

Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum

Start date: August 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if Azithromycin in combination with chloroquine is superior to chloroquine alone in eradicating P. falciparum asexual parasitemia in asymptomatic, semi-immune adults in Western Kenya.